BCL2 and B-cell chronic lymphocytic leukemia: The rational for these combinations is that, contrasting with CLL, FL, MCL, and Waldenström macroglobulinemia, which are marked by high levels of BCL-2 and malignant cells largely depend on this molecule for survival/resistance to death, in other hematological malignancies (including DLBCL, ALL, MM, AML, and CML), this anti-apoptotic molecule exhibits a more varied pattern of expression and its contribution to cell resistance to death is not ubiquitous.